Repurposing of Drugs for Cardiometabolic Disorders: An Out and Out Cumulation
January 2023
in “
Hormone and Metabolic Research
”
TLDR Existing drugs are being repurposed to treat cardiometabolic disorders, which is safer, faster, and cheaper than developing new drugs.
Cardiometabolic disorders (CMD), including insulin resistance, diabetes mellitus, hypertension, obesity, and dyslipidemia, are leading causes of death worldwide, accounting for over 32% of global fatalities each year. However, new drug development for CMDs has been challenging due to high costs and low success rates. As an alternative, drug repositioning, a method dating back to the 1960s, is gaining interest. This involves using existing drugs for new therapeutic indications. The advantage of repositioning is that the safety profile of the drug is already known, reducing the risk of failure due to toxic effects. Additionally, repositioning is less time-consuming and costly than new drug development.
